For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Wave Life Sciences Ltd (NASDAQ: WVE) was $13.91 for the day, up 0.51% from the previous closing price of $13.84. In other words, the price has increased by $0.51 from its previous closing price. On the day, 6.12 million shares were traded. WVE stock price reached its highest trading level at $14.22 during the session, while it also had its lowest trading level at $13.75.
Ratios:
Our analysis of WVE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.51 and its Current Ratio is at 2.51. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In the most recent recommendation for this company, Wedbush on December 12, 2025, Reiterated its Outperform rating but revised its target price to $33 from $20 previously.
On December 09, 2025, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform but kept the price unchanged to $27.
On October 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $18.Wells Fargo initiated its Overweight rating on October 20, 2025, with a $18 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 02 ’26 when Francis Chris sold 9,375 shares for $16.03 per share. The transaction valued at 150,260 led to the insider holds 25,000 shares of the business.
GSK plc bought 1,470,000 shares of WVE for $27,930,000 on Dec 11 ’25. The 10% Owner now owns 18,245,691 shares after completing the transaction at $19.00 per share. On Dec 08 ’25, another insider, Rawcliffe Adrian, who serves as the Director of the company, sold 42,000 shares for $15.00 each. As a result, the insider received 630,000 and left with 12,700 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WVE now has a Market Capitalization of 2583920128 and an Enterprise Value of 2156926720. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.30 while its Price-to-Book (P/B) ratio in mrq is 17.90. Its current Enterprise Value per Revenue stands at 19.747 whereas that against EBITDA is -16.285.
Stock Price History:
The Beta on a monthly basis for WVE is -1.79, which has changed by 0.24348605 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, WVE has reached a high of $21.73, while it has fallen to a 52-week low of $5.28. The 50-Day Moving Average of the stock is 16.75%, while the 200-Day Moving Average is calculated to be 62.94%.
Shares Statistics:
WVE traded an average of 6.66M shares per day over the past three months and 4293800 shares per day over the past ten days. A total of 160.29M shares are outstanding, with a floating share count of 147.79M. Insiders hold about 19.24% of the company’s shares, while institutions hold 75.44% stake in the company. Shares short for WVE as of 1767139200 were 14692409 with a Short Ratio of 2.21, compared to 1764288000 on 16026900. Therefore, it implies a Short% of Shares Outstanding of 14692409 and a Short% of Float of 10.190000000000001.
Earnings Estimates
A detailed examination of Wave Life Sciences Ltd (WVE) is currently in progress, with 12.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.29 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.02 and -$1.27 for the fiscal current year, implying an average EPS of -$1.18. EPS for the following year is -$1.19, with 13.0 analysts recommending between -$0.65 and -$1.62.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 15 analysts. It ranges from a high estimate of $47M to a low estimate of $7.61M. As of. The current estimate, Wave Life Sciences Ltd’s year-ago sales were $83.75M
A total of 15 analysts have provided revenue estimates for WVE’s current fiscal year. The highest revenue estimate was $72.5M, while the lowest revenue estimate was $33.09M, resulting in an average revenue estimate of $42.91M. In the same quarter a year ago, actual revenue was $108.3M
